Analogous to the use of DNA demethylating agents, therapeutic interventions that enhance TET2 enzymatic activity, decrease 2-HG inhibition, or restore TET2 transcription may be clinically beneficial in hematological malignancies. This evidence concerns the gene TET2 and hematologic disorder.